Durvalumab: tested in a combination

295 studies: another drug in the study is under test too. Page 2 of 3. Open to participants first (78), then studies with results posted, then the rest; newest registration first within each.

• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results postedReport a problem
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingNCT03298451Phase 3Results postedReport a problem
• Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerTerminatedNCT03237377Phase 2Results postedReport a problem
• Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyTerminatedNCT03199040Phase 1Results postedReport a problem
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03174275Phase 2Results postedReport a problem
• Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).Active, not recruitingNCT03164616Phase 3Results postedReport a problem
• A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal CancerCompletedNCT03122509Phase 2Results postedReport a problem
• Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung OriginCompletedNCT03095274Phase 2Results postedReport a problem
• Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.CompletedNCT03085225Phase 1Results postedReport a problem
• An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.CompletedNCT03084471Phase 3Results postedReport a problem
• A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaTerminatedNCT03075527Phase 2Results postedReport a problem
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active, not recruitingNCT03043872Phase 3Results postedReport a problem
• A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerCompletedNCT03015129Phase 2Results postedReport a problem
• A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell LymphomaCompletedNCT03003520Phase 2Results postedReport a problem
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results postedReport a problem
• Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic AdenocarcinomaCompletedNCT02879318Phase 2Results postedReport a problem
• Durvalumab and Tremelimumab in Patients With Advanced Rare TumoursCompletedNCT02879162Phase 2Results postedReport a problem
• Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal CancerCompletedNCT02870920Phase 2Results postedReport a problem
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results postedReport a problem
• Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesCompletedNCT02815995Phase 2Results postedReport a problem
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaTerminatedNCT02807454Phase 2Results postedReport a problem
• Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant GliomaCompletedNCT02794883Phase 2Results postedReport a problem
• Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate CancerCompletedNCT02788773Phase 2Results postedReport a problem
• Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryCompletedNCT02754856Phase 1Results postedReport a problem
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal CancerCompletedNCT02735239Phase 1/2Results postedReport a problem
• Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantTerminatedNCT02716805Phase 1Results postedReport a problem
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT02706405Phase 1Results postedReport a problem
• Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung CancerCompletedNCT02701400Phase 2Results postedReport a problem
• A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaCompletedNCT02685826Phase 1/2Results postedReport a problem
• A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersCompletedNCT02643303Phase 1/2Results postedReport a problem
• MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural MesotheliomaCompletedNCT02592551Phase 2Results postedReport a problem
• Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal CarcinomaCompletedNCT02583477Phase 1/2Results postedReport a problem
• Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal CarcinomaCompletedNCT02558894Phase 2Results postedReport a problem
• Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck CancerCompletedNCT02551159Phase 3Results postedReport a problem
• Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active, not recruitingNCT02542293Phase 3Results postedReport a problem
• MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast CancerCompletedNCT02536794Phase 2Results postedReport a problem
• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2Results postedReport a problem
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerActive, not recruitingNCT02516241Phase 3Results postedReport a problem
• Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive TumoursCompletedNCT02454933Phase 3Results postedReport a problem
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT02453282Phase 3Results postedReport a problem
• Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerCompletedNCT02431559Phase 1/2Results postedReport a problem
• Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck CancerCompletedNCT02369874Phase 3Results postedReport a problem
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02352948Phase 3Results postedReport a problem
• A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaCompletedNCT02340975Phase 1/2Results postedReport a problem
• Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and NeckCompletedNCT02319044Phase 2Results postedReport a problem
• Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic CancerCompletedNCT02311361Phase 1/2Results postedReport a problem
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT02250326Phase 2Results postedReport a problem
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results postedReport a problem
• A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabCompletedNCT01975831Phase 1Results postedReport a problem
• Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07081633Phase 2Report a problem
• A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular CarcinomaWithdrawnNCT06994299Phase 2Report a problem
• A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in SpainActive, not recruitingNCT06746116Phase 3Report a problem
• Single cEll pRofiling PErsistaNce To ImmuNothErapyActive, not recruitingNCT06680739Phase 2Report a problem
• Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTCActive, not recruitingNCT06490107Phase 2Report a problem
• NEO-adjuvant Chemo-immunotherapy in Pancreatic CancerActive, not recruitingNCT06094140Phase 2Report a problem
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2Report a problem
• Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation ProcedureActive, not recruitingNCT06045975Phase 2Report a problem
• A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2Report a problem
• Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic CholangiocarcinomaWithdrawnNCT06017297Phase 2Report a problem
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2Report a problem
• BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsActive, not recruitingNCT05943106Phase 3Report a problem
• Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3Report a problem
• Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)Active, not recruitingNCT05856695Phase 2Report a problem
• A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C MutationsWithdrawnNCT05848843Phase 1Report a problem
• Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic RadiotherapyActive, not recruitingNCT05796089Phase 2Report a problem
• Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical SurgeryActive, not recruitingNCT05713838Phase 2Report a problem
• SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruitingNCT05701488Phase 1Report a problem
• Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal CancerActive, not recruitingNCT05667298Phase 1Report a problem
• Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes AlterationsActive, not recruitingNCT05659914Phase 2Report a problem
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)Active, not recruitingNCT05629585Phase 3Report a problem
• Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung CancerWithdrawnNCT05572476Phase 2Report a problem
• Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive, not recruitingNCT05557838Phase 3Report a problem
• Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)Active, not recruitingNCT05451043Phase 2Report a problem
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1Report a problem
• Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLCSuspendedNCT05403723Phase 1Report a problem
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2Report a problem
• An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2Report a problem
• PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerStatus unknownNCT05325684Phase 1/2Report a problem
• Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2Report a problem
• An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in ChineseStatus unknownNCT05245994Phase 2Report a problem
• Chemo-free BRCA-targeted Neoadjuvant StrategyWithdrawnNCT05209529Phase 2Report a problem
• Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT TrialWithdrawnNCT05161533Phase 2Report a problem
• Sarcomas and DDR-Inhibition; a Combined Modality StudyTerminatedNCT05116254Phase 1Report a problem
• Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCActive, not recruitingNCT05092412Phase 2Report a problem
• TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2Report a problem
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCActive, not recruitingNCT05043090Phase 3Report a problem
• Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT05034887Phase 2Report a problem
• The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04961918Phase 2Report a problem
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3Report a problem
• Olaparib, Durvalumab and UV1 in Relapsed Ovarian CancerActive, not recruitingNCT04742075Phase 2Report a problem
• Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2Report a problem
• Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2Report a problem
• Combining Epigenetic And Immune Therapy to Beat Cancer.CompletedNCT04705818Phase 2Report a problem
• Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.CompletedNCT04688151Phase 1Report a problem
• Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung CancerCompletedNCT04660097Phase 2Report a problem
• Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant TreatmentWithdrawnNCT04625699Phase 2Report a problem
• Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerActive, not recruitingNCT04607954Phase 2Report a problem
• Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical StudyStatus unknownNCT04517526Phase 2Report a problem
• Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2Report a problem
• Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1Report a problem

← Durvalumab